Evidence map›Paper›PMID 30007991›Full record

SynthesisMedical science monitor : international medical journal of experimental and clinical research2018

Investigation of miR-490-3p Expression in Hepatocellular Carcinoma Based on Reverse Transcription-Polymerase Chain Reaction (RT-qPCR) and a Meta-Analysis of 749 Cases.

Ming-Fen Li, Jing-Jing Zeng, Ai-Ping Pan, Ying-Hui Lin, Hong-Sheng Lin, Rong-Zhen Zhang, Lei Yang, Yu Zhang, Yi-Wu Dang, Gang Chen

Open access · hybridAbstract readMeta-Analysis
In one paragraph

Synthesis in Medical science monitor : international medical journal of experimental and clinical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Ming-Fen LiClinical Laboratory, First Affiliated Hospital of the University of Chinese Medicine in Guangxi, Nanning, Guangxi, China (mainland).
Jing-Jing ZengDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China (mainland).
Ai-Ping PanClinical Laboratory, First Affiliated Hospital of the University of Chinese Medicine in Guangxi, Nanning, Guangxi, China (mainland).
Ying-Hui LinClinical Laboratory, First Affiliated Hospital of the University of Chinese Medicine in Guangxi, Nanning, Guangxi, China (mainland).
Hong-Sheng LinClinical Laboratory, First Affiliated Hospital of the University of Chinese Medicine in Guangxi, Nanning, Guangxi, China (mainland).
Rong-Zhen ZhangDepartment of Hepatology, First Affiliated Hospital of the University of Chinese Medicine in Guangxi, Nanning, Guangxi, China (mainland).
Lei YangClinical Laboratory, First Affiliated Hospital of the University of Chinese Medicine in Guangxi, Nanning, Guangxi, China (mainland).
Yu ZhangDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China (mainland).
Yi-Wu DangDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China (mainland).
Gang ChenDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China (mainland).
First Affiliated Hospital of GuangXi Medical University · CNGuangxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND miR-490-3p could play vital roles in multiple cancers. However, the role of miR-490-3p in hepatocellular carcinoma (HCC) remains uncertain. In this study, we sought to explore the underlying role of miR-490-3p in HCC. MATERIAL AND METHODS In this study, we explored the clinical role of miR-490-3p in HCC via quantitative reverse transcription-polymerase chain reaction (RT-qPCR) and The Cancer Genome Atlas (TCGA) database. Then, a meta-analysis was performed to evaluate the expression trend and diagnostic value of miR-490-3p in HCC. Furthermore, 12 miRNA prediction algorithms were applied to predict the potential target genes of miR-490-3p. The differentially expressed genes in HCC in the Gene Expression Profiling Interactive Analysis (GEPIA) database were also selected. Additionally, bioinformatics analyses were utilized to investigate the possible functions and pathways of the target genes. RESULTS miR-490-3p was clearly down-regulated in HCC based on RT-qPCR (P=0.002). Consistent with the results of RT-qPCR, miR-490 was more highly expressed in normal liver tissue than in HCC (P<0.001). Additionally, the meta-analysis confirmed the results from RT-qPCR and TCGA. Furthermore, based on the prediction algorithms and GEPIA, a total of 113 genes were selected. According to the bioinformatics analyses, we found that the most remarkably enriched functional terms included protein transport, poly(A) RNA binding, and intracellular organelle part. Additionally, the miR-490-3p target genes were significantly related to the pathways in cancer. CONCLUSIONS We found that miR-490-3p is down-regulated in HCC and is related to genes that have potential tumoral functions. However, the exact mechanism should be confirmed by functional experiments.

Indexed as

Carcinoma, HepatocellularDown-RegulationGene Expression Regulation, NeoplasticHumansLiver NeoplasmsMicroRNAsReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionReverse TranscriptionMicroRNAsMIRN590 microRNA, human

Identifiers

PMID30007991
PMCPMC6067044
OpenAlexW2883773825

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.